Brief: Clinuvel Pharmaceuticals Posts HY Net Profit Attributable Down 4% To A$10.9 Mln
22/02/2024 01:19
Feb 22 (Reuters) - Clinuvel Pharmaceuticals Ltd
CUV.AX :
* HY NET PROFIT ATTRIBUTABLE DECREASED 4% TO A$10.9 MILLION
Further company coverage: CUV.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clinuvel Pharmaceuticals
See all newsBrief: Clinuvel Pharmaceuticals Announces Strategic Reorganisation To Refocus On U.S. Markets
Brief: Clinuvel Pharmaceuticals Ltd's ADS To Commence Trading On Nasdaq
Brief: Clinuvel Pharmaceuticals Says Scenesse Approved For EPP In Canada
Australia's Clinuvel Pharmaceuticals rises on Canada nod for phototoxicity prevention drug
Brief: Clinuvel Pharmaceuticals Updates On Level II ADR Upgrade, Nasdaq Uplist